BRAF and melanoma: In 2022, Franklin et al. analyzed the impact of radiation therapy in a large real-world cohort of 450 patients diagnosed with melanoma brain metastases (MBMs) and receiving three different schedules of first-line systemic therapy (combined CTLA-4 and PD-1 blockade, PD1 blockade monotherapy, or BRAF+MEKTT).